Great Connections and Insight Provided at NGS for Drugs, Patients and Clinical Trials 2013!
Cambridge Healthtech Institute would like to thank the speaking faculty, attendees, sponsors and exhibitors who helped make this meeting such a success! The two-day meeting convened prominent scientists from across large pharma and biotechs to share insight and real-world strategies for using NGS to advance research and development. As a special feature, we proudly welcomed NIST to present an update on the efforts of Genome in a Bottle Consortium, which developed widely accepted reference materials and accompanying performance metrics to provide a strong scientific foundation for the development of regulations and professional standards for clinical sequencing.
If you would like to share your feedback, or give input for future events, please contact Kip Harry at email@example.com
Next-Generation Sequencing (NGS) – along with a shift toward personalized medicine – is poised to revolutionize the drug discovery paradigm by offering unprecedented interrogation of the human genome at high resolution, and relatively low costs. While the widespread implementation of NGS is apparent, issues specific to drug development present new challenges for developers, including discerning actionable genomic information for novel targets, markers and utilization in clinical trials; developing informatics infrastructure and pipelines to deal with the computational complexity of NGS data; and navigating regulatory hurdles of informed consent and data sharing. Cambridge Healthtech Institute is proud to announce the inaugural NGS for Drugs, Patients and Clinical Trials, designed with drug developers in mind, to address the unparalleled advantages of NGS technologies for translational research, while addressing common challenges.
NGS for Drugs, Patients and Clinical Trials delivers:
- The latest developments in reference materials, methods and data from NIST's Genome in a Bottle Consortium
- How big pharma is navigating the complexity of NGS data for actionable information
- Pfizer's approach for addressing tumor heterogeneity and differential drug response using NGS
- Advantages of deep sequencing from MedImmune and GSK for hard to identify mutations
- First-hand examples of the utilization of NGS for target discovery and validation from Sanofi and GSK
- Gilead, Biogen and Astrazeneca's approach to simplifying biomarker discovery
- Abbott and Regulus' incorporation of NGS technologies for the development of Biologics
- Insight into setting up, running and managing a CAP/CLIA certified facility
Profiling and NGS in Cancer: Challenges and Applications to Targets, Models, and Resistance
Paul Rejto, Ph.D., Director, Computational Biology, Oncology Research Unit, Pfizer, Inc.
Devising Methods for Intuitively Handling Huge Data Sets to Simplify Biomarker Discovery
Dongliang Ge, Ph.D., Director, Bioinformatics, Gilead Sciences, Inc.
SPECIAL MORNING SESSION
Genome in a Bottle Consortium
Thursday, March 21